Developer docs
API playgroundTry for free, no card

Search company profiles

Minerva Imaging

Full company profile

uuid0006t31

Namestring
Minerva Imaging
Legal namestring
Minerva Imaging ApS
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Minerva Imaging ApS is a Danish contract research and manufacturing organization founded in 2011, headquartered in Ølstykke, Denmark. The company operates as a fully integrated CRO and CDMO specializing in targeted radionuclide therapies and molecular imaging for cancer drug development. Its scientific capabilities derive from more than two decades of research at the University of Copenhagen and Rigshospitalet, with a team of 150+ professionals including a significant number of PhD-level scientists spanning radiochemistry, pharmacology, oncology, and imaging.

The company offers an end-to-end preclinical service portfolio including oncology study design and execution (PDX, syngeneic, and xenograft models), targeted radionuclide therapy studies across alpha and beta emitters (Lu-177, Tb-161, Ac-225, Th-227), molecular imaging (PET, SPECT, CT, MRI), in vivo pharmacology in rodent and large animal models, in vitro and ex vivo capabilities (flow cytometry, histology, immunohistochemistry), and cardiovascular disease research. The CDMO arm provides GMP-certified radiopharmaceutical manufacturing, CMC services, tech transfer, and clinical trial material production. Technology infrastructure includes a GE Healthcare PETtrace 880 cyclotron, GMP-compliant radiochemistry laboratory, surgical theater, the Alpha-SPECT Mini system for alpha-emitter imaging, and the Atley Solutions C100 module for Astatine-211 handling. Revenue is generated through professional services contracts and managed CDMO engagements with pharmaceutical and biotechnology clients, priced on a quote basis. Disclosed revenue reached DKK 225 million in 2024, with Nordic Capital taking a partnership stake in June 2025 to support international expansion.

Short descriptiontext

Minerva Imaging is a Danish integrated CRO and CDMO that provides preclinical oncology, molecular imaging, and GMP radiopharmaceutical manufacturing services to pharmaceutical and biotechnology companies developing targeted radionuclide therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersØlstykke, Denmark
HQ citystring
Ølstykke
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, radiopharmaceutical CDMO, molecular imaging services, targeted radionuclide therapy, preclinical oncology research
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Preclinical CRO/CDMO Services (Radiopharmaceutical & Molecular Imaging)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Preclinical research services including oncology studies, radionuclide therapy studies, molecular imaging, and pharmacology studies for pharmaceutical and biotechnology companies.

minervaimaging.com
2Contract Development and Manufacturing (CDMO)
TypeManaged Services
Description

GMP manufacturing of radiopharmaceutical drugs and tracers for clinical trials. First clinical dose shipped from CDMO for Phase II clinical trial in 2024.

minervaimaging.com
3GMP Radiopharmaceutical Manufacturing
TypeManaged Services
Description

Manufacturing of radiopharmaceutical drugs for clinical use including radiolabeling, process validations, and clinical manufacturing activities.

minervaimaging.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Minerva Imaging is a scientifically driven CRO and CDMO specializing in targeted radiopharmaceutical therapies and molecular imaging for cancer drug development. The company provides integrated preclinical oncology services, GMP-certified manufacturing of radiopharmaceuticals for clinical trials, molecular imaging studies (PET, SPECT, CT, MRI), and in vitro/ex vivo pharmacology services to pharmaceutical and biotechnology companies. Founded in 2011 in Denmark, the company has built a 25+ year track record of research expertise supporting drug developers across the radiopharmaceutical value chain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Revenue of DKK 225 million in 2024
+4 more records
Product overview1 text field

Minerva Imaging operates as a fully integrated CRO and CDMO specializing in targeted radionuclide therapies for cancer treatment. The company offers a comprehensive portfolio combining preclinical research services (oncology models, molecular imaging, in vivo pharmacology, radionuclide therapy studies) with manufacturing capabilities (CDMO services, GMP-certified radiopharmaceutical production, isotope supply). Key platforms include PSMA-targeted and HER2-targeted radiopharmaceutical evaluation, breast cancer brain metastases translational models, and specialized imaging services including PET, SPECT, CT, and MRI. The company leverages partnerships (XenoSTART for PDX models, University of Copenhagen for research, Visiopharm for AI-based image analysis) and advanced technology (Alpha-SPECT Mini system, clinical 1.5T MRI, cyclotron facilities) to deliver end-to-end services from lead optimization through clinical trial material manufacturing.

Product and service10 records
1Targeted Radionuclide Therapy Services
CategoryPreclinical CRO Services
Description

Preclinical evaluation services for targeted radionuclide therapies, including biodistribution, dosimetry, efficacy, and toxicity studies in relevant oncology models. Designed for pharmaceutical and biotech companies developing radioligand and radioimmunotherapy programs.

2Preclinical Oncology Services
CategoryPreclinical CRO Services
Description

Comprehensive preclinical oncology research services leveraging multiple tumor models (syngeneic, xenograft, PDX, humanized) for efficacy, PK/PD, and mechanism-of-action studies in cancer drug development.

3Molecular Imaging Services
CategoryPreclinical CRO Services
Description

Quantitative molecular imaging services using PET, SPECT, CT, and MRI modalities to support drug development and translational research. Includes the proprietary Alpha-SPECT Mini System for high-resolution preclinical imaging.

4CDMO Services
CategoryContract Manufacturing (CDMO)
Description

GMP-certified contract development and manufacturing organization services for radiopharmaceuticals intended for clinical trials, including process development, scale-up, and aseptic manufacturing.

5In Vitro and Ex Vivo Capabilities
CategoryPreclinical CRO Services
Description

In vitro and ex vivo pharmacology services including cell-based assays, flow cytometry, and histology analyses to complement in vivo preclinical studies.

6In Vivo Pharmacology
CategoryPreclinical CRO Services
Description

In vivo pharmacology services in oncology and other disease areas, including PK/PD, biodistribution, and efficacy studies in animal models.

7Cardiovascular Disease Services
CategoryPreclinical CRO Services
Description

Preclinical imaging and pharmacology services for cardiovascular disease drug development, leveraging molecular imaging capabilities.

8Isotope Supply
CategoryRadiopharmaceutical Supply
Description

Supply of radioisotopes for research and clinical use, supported by the company's on-site cyclotron (PETtrace 880) for isotope production.

9Flow Cytometry
CategoryPreclinical CRO Services
Description

Flow cytometry services supporting preclinical research, including immunophenotyping and biomarker analysis in oncology and other disease areas.

10Histology
CategoryPreclinical CRO Services
Description

Histology services including tissue processing, staining, and pathological analysis to support preclinical drug development studies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-29
Description

Strategic collaboration integrating Debiopharm's proprietary AbYlink conjugation technology into Minerva's preclinical research platform. AbYlink enables one-step regio-selective conjugation of payloads on the Fc domain of antibodies without affecting antigen-binding domains, supporting development of next-generation radiopharmaceuticals and theranostics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-20
Description

Acquisition of MH3D's Alpha-SPECT Mini system, the first preclinical system in Europe optimized for alpha-emitter theranostics. High-performance preclinical SPECT system with CZT-based detector technology for highly sensitive imaging of alpha-emitting radiopharmaceuticals.

3University of Copenhagen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Collaboration to evaluate Terbium-161 radiopharmaceutical therapies. Preclinical biodistribution, tolerability, and efficacy evaluation of [161Tb]Tb-trastuzumab in HER2-expressing breast cancer tumors. Builds on over two decades of research partnership.

minervaimaging.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for PDX (Patient-Derived Xenograft) models enabling integrated radiopharmaceutical drug development platform. XenoSTART provides validated and characterized PDX models used for studies in orthotopic and metastatic settings involving external radiation therapy, radionuclide therapy and in vivo imaging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to accelerate precision medicine and targeted radionuclide therapy. GE Healthcare provides cyclotron technology (PETtrace 880) and collaborative support for radiopharmaceutical development and manufacturing.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration to make Astatine-211 available for targeted radionuclide drug development. Atley Solutions provides C100 module for handling Astatine-211 radiopharmaceuticals - first commercial installation at Minerva Imaging.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Supply agreement to offer CD8 ImmunoPET imaging agent to customers. Provides access to CD8 T-cell imaging capabilities for preclinical studies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partnership to re-envision digestive disease research through advanced imaging and analysis capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Consortium to revolutionize cancer care, advancing precision medicine for patients in Europe through collaborative research and development efforts.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on evaluation of OP-1250 (complete estrogen receptor antagonist) efficacy in intracranial PDX tumor model for breast cancer brain metastases research.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-phase clinical and preclinical CRO offering imaging, PK/PD, and translational services to pharma. Overlaps with Minerva's translational imaging and biodistribution capabilities across the drug development lifecycle.

TypeDirect peer
Description

Contract research organization specializing in molecular imaging and translational research for pharma/biotech drug development. Directly comparable to Minerva's preclinical imaging and oncology CRO services, including PET and SPECT capabilities.

TypeBroad incumbent
Description

Large preclinical CRO offering oncology models, in vivo imaging, and radiochemistry capabilities through its discovery and safety assessment segment. Competes with Minerva for preclinical oncology and radiopharmaceutical study work but as part of a much broader portfolio.

TypeBroad incumbent
Description

Global CRO/CDMO with preclinical, CMC, and manufacturing capabilities across biologics and small molecules, including radiolabeling services. Comparable integrated service model at significantly larger scale than Minerva.

TypeBroad incumbent
Description

Global CRO/CDMO with integrated drug discovery, preclinical, and manufacturing services including radiolabeled compounds. Comparable breadth of services but a much larger, diversified footprint than Minerva's specialized radiopharma focus.

6SOFIE Biosciences
TypeDirect peer
Description

Radiopharmaceutical CDMO and contract research provider offering GMP manufacturing, isotope supply, and preclinical imaging services. Closely mirrors Minerva's integrated CRO/CDMO model for theranostics and targeted radionuclide therapy developers.

TypeBroad incumbent
Description

Vertically integrated radiopharmaceutical manufacturer and distributor with GMP production and isotope supply. Overlaps with Minerva's CDMO and isotope-supply business but focused on commercial-scale clinical and diagnostic products.

83D Signatures (in vivo imaging arm)
TypeEmerging player
Description

Preclinical imaging CRO focused on PET, SPECT, MRI, and optical imaging for oncology drug development. Smaller-scale peer to Minerva's preclinical molecular imaging services, often competing for similar pharma translational projects.

9Covalabs
TypeDirect peer
Description

European preclinical CRO with deep expertise in antibody development, radiolabeling, and in vivo pharmacology. Comparable to Minerva's targeted radionuclide therapy and antibody-radioconjugate evaluation work.

TypeBroad incumbent
Description

Large CDMO that has publicly invested in radioligand therapy manufacturing capacity. Competes with Minerva's CDMO offering for clinical-stage radiopharmaceutical programs at a global, multi-site scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Minerva Imaging

Preclinical CRO/CDMO Services (Radiopharmaceutical & Molecular Imaging)minervaimaging.com

Minerva Imaging is a Danish integrated CRO and CDMO that provides preclinical oncology, molecular imaging, and GMP radiopharmaceutical manufacturing services to pharmaceutical and biotechnology companies developing targeted radionuclide therapies.

What Minerva Imaging does

Minerva Imaging ApS is a Danish contract research and manufacturing organization founded in 2011, headquartered in Ølstykke, Denmark. The company operates as a fully integrated CRO and CDMO specializing in targeted radionuclide therapies and molecular imaging for cancer drug development. Its scientific capabilities derive from more than two decades of research at the University of Copenhagen and Rigshospitalet, with a team of 150+ professionals including a significant number of PhD-level scientists spanning radiochemistry, pharmacology, oncology, and imaging.

The company offers an end-to-end preclinical service portfolio including oncology study design and execution (PDX, syngeneic, and xenograft models), targeted radionuclide therapy studies across alpha and beta emitters (Lu-177, Tb-161, Ac-225, Th-227), molecular imaging (PET, SPECT, CT, MRI), in vivo pharmacology in rodent and large animal models, in vitro and ex vivo capabilities (flow cytometry, histology, immunohistochemistry), and cardiovascular disease research. The CDMO arm provides GMP-certified radiopharmaceutical manufacturing, CMC services, tech transfer, and clinical trial material production. Technology infrastructure includes a GE Healthcare PETtrace 880 cyclotron, GMP-compliant radiochemistry laboratory, surgical theater, the Alpha-SPECT Mini system for alpha-emitter imaging, and the Atley Solutions C100 module for Astatine-211 handling. Revenue is generated through professional services contracts and managed CDMO engagements with pharmaceutical and biotechnology clients, priced on a quote basis. Disclosed revenue reached DKK 225 million in 2024, with Nordic Capital taking a partnership stake in June 2025 to support international expansion.

Minerva Imaging firmographics

Firmographics
Name
Minerva Imaging
Legal name
Minerva Imaging ApS
Website
https://minervaimaging.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Minerva Imaging is a Danish integrated CRO and CDMO that provides preclinical oncology, molecular imaging, and GMP radiopharmaceutical manufacturing services to pharmaceutical and biotechnology companies developing targeted radionuclide therapies.
Ownership category
akta.pro rank

Minerva Imaging industry classification

Industry
Product category
Preclinical CRO/CDMO Services (Radiopharmaceutical & Molecular Imaging)
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Preclinical CRO services
  • Radiopharmaceutical CDMO
  • Molecular imaging services
  • Targeted radionuclide therapy
  • Preclinical oncology research

Where Minerva Imaging is headquartered

Location

Headquarters

HQ city
Ølstykke
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Minerva Imaging business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Preclinical research services including oncology studies, radionuclide therapy studies, molecular imaging, and pharmacology studies for pharmaceutical and biotechnology companies.
  2. Contract Development and Manufacturing (CDMO): GMP manufacturing of radiopharmaceutical drugs and tracers for clinical trials. First clinical dose shipped from CDMO for Phase II clinical trial in 2024.
  3. GMP Radiopharmaceutical Manufacturing: Manufacturing of radiopharmaceutical drugs for clinical use including radiolabeling, process validations, and clinical manufacturing activities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Minerva Imaging product offering

Product offering

Core offering

Minerva Imaging is a scientifically driven CRO and CDMO specializing in targeted radiopharmaceutical therapies and molecular imaging for cancer drug development. The company provides integrated preclinical oncology services, GMP-certified manufacturing of radiopharmaceuticals for clinical trials, molecular imaging studies (PET, SPECT, CT, MRI), and in vitro/ex vivo pharmacology services to pharmaceutical and biotechnology companies. Founded in 2011 in Denmark, the company has built a 25+ year track record of research expertise supporting drug developers across the radiopharmaceutical value chain.

Product overview

Minerva Imaging operates as a fully integrated CRO and CDMO specializing in targeted radionuclide therapies for cancer treatment. The company offers a comprehensive portfolio combining preclinical research services (oncology models, molecular imaging, in vivo pharmacology, radionuclide therapy studies) with manufacturing capabilities (CDMO services, GMP-certified radiopharmaceutical production, isotope supply). Key platforms include PSMA-targeted and HER2-targeted radiopharmaceutical evaluation, breast cancer brain metastases translational models, and specialized imaging services including PET, SPECT, CT, and MRI. The company leverages partnerships (XenoSTART for PDX models, University of Copenhagen for research, Visiopharm for AI-based image analysis) and advanced technology (Alpha-SPECT Mini system, clinical 1.5T MRI, cyclotron facilities) to deliver end-to-end services from lead optimization through clinical trial material manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Targeted Radionuclide Therapy Services Preclinical evaluation services for targeted radionuclide therapies, including biodistribution, dosimetry, efficacy, and toxicity studies in relevant oncology models. Designed for pharmaceutical and biotech companies developing radioligand and radioimmunotherapy programs.
  • Preclinical Oncology Services Comprehensive preclinical oncology research services leveraging multiple tumor models (syngeneic, xenograft, PDX, humanized) for efficacy, PK/PD, and mechanism-of-action studies in cancer drug development.
  • Molecular Imaging Services Quantitative molecular imaging services using PET, SPECT, CT, and MRI modalities to support drug development and translational research. Includes the proprietary Alpha-SPECT Mini System for high-resolution preclinical imaging.
  • CDMO Services GMP-certified contract development and manufacturing organization services for radiopharmaceuticals intended for clinical trials, including process development, scale-up, and aseptic manufacturing.
  • In Vitro and Ex Vivo Capabilities In vitro and ex vivo pharmacology services including cell-based assays, flow cytometry, and histology analyses to complement in vivo preclinical studies.
  • In Vivo Pharmacology In vivo pharmacology services in oncology and other disease areas, including PK/PD, biodistribution, and efficacy studies in animal models.
  • Cardiovascular Disease Services Preclinical imaging and pharmacology services for cardiovascular disease drug development, leveraging molecular imaging capabilities.
  • Isotope Supply Supply of radioisotopes for research and clinical use, supported by the company's on-site cyclotron (PETtrace 880) for isotope production.
  • Flow Cytometry Flow cytometry services supporting preclinical research, including immunophenotyping and biomarker analysis in oncology and other disease areas.
  • Histology Histology services including tissue processing, staining, and pathological analysis to support preclinical drug development studies.

Quantifiable outcome

  • Revenue of DKK 225 million in 2024
  • +4 more outcomes

Companies that use Minerva Imaging

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Minerva Imaging technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Minerva Imaging partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • DebiopharmcoreTechnology or Integration · 29 May 2026Strategic collaboration integrating Debiopharm's proprietary AbYlink conjugation technology into Minerva's preclinical research platform. AbYlink enables one-step regio-selective conjugation of payloads on the Fc domain of antibodies without affecting antigen-binding domains, supporting development of next-generation radiopharmaceuticals and theranostics.
  • MH3DcoreTechnology or Integration · 20 April 2026Acquisition of MH3D's Alpha-SPECT Mini system, the first preclinical system in Europe optimized for alpha-emitter theranostics. High-performance preclinical SPECT system with CZT-based detector technology for highly sensitive imaging of alpha-emitting radiopharmaceuticals.
  • University of CopenhagencoreStrategic or Co-development Partner · 26 February 2026Collaboration to evaluate Terbium-161 radiopharmaceutical therapies. Preclinical biodistribution, tolerability, and efficacy evaluation of [161Tb]Tb-trastuzumab in HER2-expressing breast cancer tumors. Builds on over two decades of research partnership.
  • XenoSTARTcoreStrategic or Co-development PartnerStrategic collaboration for PDX (Patient-Derived Xenograft) models enabling integrated radiopharmaceutical drug development platform. XenoSTART provides validated and characterized PDX models used for studies in orthotopic and metastatic settings involving external radiation therapy, radionuclide therapy and in vivo imaging.
  • GE HealthcarecoreStrategic or Co-development PartnerStrategic partnership to accelerate precision medicine and targeted radionuclide therapy. GE Healthcare provides cyclotron technology (PETtrace 880) and collaborative support for radiopharmaceutical development and manufacturing.
  • Atley SolutionscoreTechnology or IntegrationCollaboration to make Astatine-211 available for targeted radionuclide drug development. Atley Solutions provides C100 module for handling Astatine-211 radiopharmaceuticals - first commercial installation at Minerva Imaging.
  • ImaginAbminorChannel Partner/ Reseller/ DistributorSupply agreement to offer CD8 ImmunoPET imaging agent to customers. Provides access to CD8 T-cell imaging capabilities for preclinical studies.
  • Motilent LimitedminorStrategic or Co-development PartnerStrategic partnership to re-envision digestive disease research through advanced imaging and analysis capabilities.
  • Thera4Care ConsortiumcoreStrategic or Co-development PartnerConsortium to revolutionize cancer care, advancing precision medicine for patients in Europe through collaborative research and development efforts.
  • Olema OncologyminorStrategic or Co-development PartnerCollaboration on evaluation of OP-1250 (complete estrogen receptor antagonist) efficacy in intracranial PDX tumor model for breast cancer brain metastases research.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Minerva Imaging competitors and assessment

Company assessment

Direct peers

  • Celerion: Early-phase clinical and preclinical CRO offering imaging, PK/PD, and translational services to pharma. Overlaps with Minerva's translational imaging and biodistribution capabilities across the drug development lifecycle.
  • Invicro: Contract research organization specializing in molecular imaging and translational research for pharma/biotech drug development. Directly comparable to Minerva's preclinical imaging and oncology CRO services, including PET and SPECT capabilities.
  • SOFIE Biosciences: Radiopharmaceutical CDMO and contract research provider offering GMP manufacturing, isotope supply, and preclinical imaging services. Closely mirrors Minerva's integrated CRO/CDMO model for theranostics and targeted radionuclide therapy developers.
  • Covalabs: European preclinical CRO with deep expertise in antibody development, radiolabeling, and in vivo pharmacology. Comparable to Minerva's targeted radionuclide therapy and antibody-radioconjugate evaluation work.

Broad incumbents

  • Charles River Laboratories: Large preclinical CRO offering oncology models, in vivo imaging, and radiochemistry capabilities through its discovery and safety assessment segment. Competes with Minerva for preclinical oncology and radiopharmaceutical study work but as part of a much broader portfolio.
  • WuXi AppTec: Global CRO/CDMO with preclinical, CMC, and manufacturing capabilities across biologics and small molecules, including radiolabeling services. Comparable integrated service model at significantly larger scale than Minerva.
  • Pharmaron: Global CRO/CDMO with integrated drug discovery, preclinical, and manufacturing services including radiolabeled compounds. Comparable breadth of services but a much larger, diversified footprint than Minerva's specialized radiopharma focus.
  • Curium: Vertically integrated radiopharmaceutical manufacturer and distributor with GMP production and isotope supply. Overlaps with Minerva's CDMO and isotope-supply business but focused on commercial-scale clinical and diagnostic products.
  • Lonza Radioligand Therapy: Large CDMO that has publicly invested in radioligand therapy manufacturing capacity. Competes with Minerva's CDMO offering for clinical-stage radiopharmaceutical programs at a global, multi-site scale.

Emerging players

  • 3D Signatures (in vivo imaging arm): Preclinical imaging CRO focused on PET, SPECT, MRI, and optical imaging for oncology drug development. Smaller-scale peer to Minerva's preclinical molecular imaging services, often competing for similar pharma translational projects.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Minerva Imaging social profiles

Digital presence

Minerva Imaging compliance and trust

Trust signal

Compliance3 records

Minerva Imaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Minerva Imaging leadership team

Management profile

Number of profiles

Profiles11 records

Minerva Imaging subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Minerva Imaging funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Minerva Imaging M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minerva Imaging

What does Minerva Imaging do?

Minerva Imaging is a scientifically driven CRO and CDMO specializing in targeted radiopharmaceutical therapies and molecular imaging for cancer drug development. The company provides integrated preclinical oncology services, GMP-certified manufacturing of radiopharmaceuticals for clinical trials, molecular imaging studies (PET, SPECT, CT, MRI), and in vitro/ex vivo pharmacology services to pharmaceutical and biotechnology companies. Founded in 2011 in Denmark, the company has built a 25+ year track record of research expertise supporting drug developers across the radiopharmaceutical value chain.

Is Minerva Imaging a public or private company?

Minerva Imaging is a private company. It is classified as private equity controlled and is currently operating.

When was Minerva Imaging founded?

Minerva Imaging was founded in 2011. It employs 101 to 250 people.

Where is Minerva Imaging based?

Minerva Imaging is headquartered in Ølstykke, Denmark, in the Europe region.

How does Minerva Imaging make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Development and Manufacturing (CDMO) and GMP Radiopharmaceutical Manufacturing.

Who are Minerva Imaging's main competitors?

Direct peers on record are Celerion, Invicro, SOFIE Biosciences and Covalabs. Broad incumbents are Charles River Laboratories, WuXi AppTec, Pharmaron, Curium and Lonza Radioligand Therapy. 3D Signatures (in vivo imaging arm) is listed as an emerging player.

Does Minerva Imaging have an API?

No public API is recorded for Minerva Imaging.

What industry is Minerva Imaging in?

Minerva Imaging's product category is Preclinical CRO/CDMO Services (Radiopharmaceutical & Molecular Imaging). Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireTD2 Oncology and Minerva Imaging Partner to Expand Radiopharmaceutical Development SupportTD2 Oncology and Minerva Imaging announced a partnership to integrate radiopharmaceutical development activities, combining TD2's clinical and regulatory expertise with Minerva's CDMO and imaging services. The collaboration aims to support sponsors in advancing radioligand therapy programs from translational strategy to first-in-human trials, and the partnership is now active.PR NewswireTranslational Imaging to Accelerate Cardiovascular Drug Development, Upcoming Webinar Hosted by XtalksXtalks, a life science industry media platform, is hosting a free webinar on April 8, 2026, focused on how advanced cardiovascular imaging and translational biomarkers can improve drug development by bridging preclinical animal studies with clinical cardiology practice. The webinar will feature speakers from Minerva Imaging and academic institutions, covering cardiac MRI techniques, disease model induction, and histology workflows designed to reduce translational gaps in cardiovascular therapy development.EIN PresswirePatient-Derived Xenograft (PDX) Models Market Driving Precision Oncology and Translational Cancer ResearchThe global Patient-Derived Xenograft (PDX) Models Market is projected to grow during the forecast period, driven by increasing oncology drug pipelines, rising cancer prevalence, and expanding R&D investments by pharmaceutical and biotechnology companies. Recent market developments include Crown Bioscience opening a Model Development Center in North Carolina, Charles River Laboratories completing the acquisition of Oncodesign, Thermo Fisher Scientific acquiring Cognate BioServices, and multiple strategic collaborations such as XenoSTART with Minerva Imaging and Crown Bioscience with Jiangsu Hengrui Medicine. North America currently dominates the market while the Asia-Pacific region is emerging as the fastest-growing market.PR NewswireXenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development PlatformXenoSTART and Minerva Imaging expanded their decade-long partnership to create an integrated platform for radiopharmaceutical drug development, combining XenoSTART's clinically annotated patient-derived xenograft models with Minerva Imaging's imaging and manufacturing capabilities. The collaboration aims to accelerate discovery and reduce risk in oncology, particularly for prostate cancer.YahooXenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development PlatformXenoSTART and Minerva Imaging expanded their decade-long partnership to create an integrated platform for radiopharmaceutical drug development, combining XenoSTART's clinically annotated patient-derived xenograft models with Minerva Imaging's imaging and manufacturing capabilities. The collaboration aims to accelerate discovery and reduce risk in oncology, particularly for prostate cancer.MinervaimagingPRESS RELEASE: Nordic Capital to partner with Minerva Imaging, to support its growth journey in the radiopharmaceutical spaceNordic Capital will partner with Minerva Imaging to support its growth in radiopharmaceuticals, with terms undisclosed. The investment is expected to complete in Q3 2025, subject to regulatory approvals. Minerva, a CRO/CDMO, generated over DKK 225 million in revenue in 2024.